School of Medicine

Chancellor Andrew D. Martin has appointed a committee to begin the process of identifying the next dean of WashU Medicine. David H. Perlmutter, MD, will conclude his deanship in June 2026.

Randall Jotte, MD, a professor of emergency medicine at WashU Medicine, is a driving force behind the innovative Hospital to Housing program to stabilize the lives of high-frequency users of hospital emergency rooms.

Renowned physician-scientist and pharmaceutical executive P. Roy Vagelos, MD, and his wife, Diana, have pledged $15 million to support the Medical Scientist Training Program (MSTP) at WashU Medicine. In recognition of the couple’s generosity, the program has been named the Roy Vagelos Medical Scientist Training Program.

WashU Medicine researchers have identified biomarkers of Alzheimer’s, Parkinson’s and frontotemporal dementia from blood plasma, suggesting new therapeutic avenues.

Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor and vice chair of innovation and translation in WashU Medicine’s John F. Hardesty, MD, Department of Ophthalmology & Visual Sciences, has received the 2025 Retina Research Foundation’s Gertrude D. Pyron Award.

The Division of Physician-Scientists at WashU Medicine has selected four physicians for its sixth class of Dean’s Scholars. The awardees will receive up to two years of financial support and mentorship, as well as dedicated lab time to conduct scientific research.

Ana Maria Arbeláez, MD, and Stephanie A. Fritz, MD, have been named co-vice chairs of clinical investigation in the Department of Pediatrics at WashU Medicine.

A new study from WashU Medicine researchers describes the structure of an important protein that unspools the DNA molecule so the DNA can be repaired. Interfering with the protein could prove useful in developing new therapeutics for tuberculosis or other diseases caused by organisms that rely on these proteins to repair their DNA.

Two recent studies from researchers at WashU Medicine reveal that two vulnerable populations — children and recently pregnant women — face disparities in access to treatment for hepatitis C infection, putting them at risk of long-term health problems.

WashU Medicine researchers led by Siyuan Ding identified an immune-system protein in human cells that has the unusual capacity to respond to both DNA and RNA from pathogens, which may have implications for developing vaccines.